3D bioprinting is pioneering new approaches in tissue engineering and regenerative medicine, offering transformative potential for treating damaged or diseased tissues and organs. This technology enables the development of complex 3D structures that closely replicate natural tissues, with applications ranging from organ replacement to drug testing. Bioprinted tissues provide reliable platforms for preclinical drug testing, disease modelling, and potentially address organ donor shortages. However, translating 3D bioprinting to clinical settings presents significant challenges. These include scalability issues, limited vascularization in larger tissues, biocompatibility concerns, and immune rejection risks associated with synthetic materials Additionally, the regulatory landscape is still evolving, with preclinical and clinical testing required to ensure safety and efficacy. Technical hurdles in bioprinting methods and bioink formulation further complicate the process, affecting cell viability, mechanical properties, and biological functionality. Each bioprinting technique has inherent limitations, impacting its efficiency, resolution, and suitability for creating viable tissues. This review highlights the current advancements in 3D bioprinting, potential clinical applications, and critical challenges that must be addressed to enable the successful clinical translation of this technology. By examining these obstacles and proposing future research directions, this review contributes to the development of strategies aimed at integrating 3D bioprinting into clinical practice.